Pulmonary Hypertension Secondary to COPD

<table class="table-group" id="tab5"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left" rowspan="2">
						Inhaled</td><td align="center" colspan="2">Systemically delivered</td></tr><tr class="thead"><td align="center">Nonspecific</td><td align="center">Specific</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">O<sub>2</sub></td><td align="center">CCB: nifedipine, felodipine</td><td align="center">PDE5 I: sildenafil</td></tr><tr><td align="left">NO</td><td align="center"><i>α</i>-1 antagonist: prazosin</td><td align="center">ETRA: bosentan</td></tr><tr><td align="left">PG:  iloprost</td><td align="center">ACEI: captopril</td><td align="center"> </td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>PH: pulmonary hypertension, O<sub>2</sub>: oxygen, NO: nitric oxide, PG: prostaglandin, CCB: calcium channel blocker, ACEI: angiotensin converting enzyme inhibitor, PDE5 I: phosphodiesterase 5 inhibitor, ETRA: endothelin receptor antagonist.<br/></td></tr></table>

Various pulmonary vasodilators studied for the treatment of PH in COPD.

Pulmonary Medicine

tab5

Table 5

Table 5: Pulmonary Hypertension Secondary to COPD 